Kornimate/medical-research-clean huggingface dataset:
investigation of hepatitis b and hepatitis c in taiwan

Conditions: Hepatitis B; Hepatitis C

Summary: the purpose of this study is to investigate the differences of genotypes of hepatitis b and hepatitis c in taiwan.

the purpose of this study is investigating the differences of genotypes and dna level or rna level of hepatitis b and hepatitis c in taiwan.

Eligibility criteria:
inclusion criteria: * born before 1985/01/01 * hbv or hcv carriers exclusion criteria: * n/a

Keywords: hepatitis b hepatitis c genotype dna level rna level taiwan
impact of prolonged physical therapy on gait performance of chronic phase stroke patients

Conditions: Hemiplegia

Summary: the aim of this multi-center, randomized controlled study is to acquire and compare information on gait performance in patients with chronic hemiplegia (six months to two years post-stroke) who either continue to attend two physical therapy sessions per week for two months or who stop physical therapy sessions for two months.following the initial screening, subjects will be randomized into two groups: one who continues attending two physical therapy sessions per week for two months, or the other one who stops physical therapy sessions for two months. before and after those two months, a 3 days recording will be made using an ambulatory system called trident.

the aim of this multi-center, randomized controlled study is to acquire and compare information on gait performance in patients with chronic hemiplegia (six months to two years post-stroke) who either continue to attend two physical therapy sessions per week for two months or who stop physical therapy sessions for two months. this will permit us 1) to assess the efficacy of continuing physical therapy sessions during the chronic phase of post-stroke hemiplegia, 2) to investigate whether the effects of physical therapy in these patients gradually decreases during the period of six months to two years post-stroke, and 3) to model the relationship between standard measures of gait performance (speed, endurance, balance, use of technical aids...) with other multidimensional covariates: social and environmental factors (type of housing, presence of a third person,...), cognitive factors (cognitive disorders associated) and thymic factors (anxiety, depression) and 4) to assess the costs associated with the physical therapy care of chronic-phase stroke patients .

Eligibility criteria:
inclusion criteria: * patients must be aged 18 to 75 years, with a first ischemic or hemorrhagic stroke at least six months ago and no longer than two years ago, without subsequent stroke. it must have caused initially complete hemiplegia of the right or left hemibody, but they must be able of walk alone with or without technical assistance over a distance of at least 10 meters they must be able change direction too. * finally, they must have a functional ambulation classification (fac) score between 4 and 6 during the inclusion. exclusion criteria: * we will exclude patients with a neurological history other than a stroke, a psychiatric illness, or an associated debilitating disease. * they must not have an associated cerebella syndrome or a clinical brainstem attack. * we will refuse patients who are pregnant, who have not signed the written consent, and who aren't entitled to a social security scheme.

Keywords: hemiplegia stroke trident
a randomized, single-blind, controlled clinical study of cardiomyopeptidin on improving ischemia-reperfusion injury in patients with acute st-segment elevation myocardial infarction after primary pci

Conditions: Cardiovascular Diseases

Summary: this study aim to investigate the myocardium protection effect of cardiomyopeptidin in patients undergoing primary pci for st-elevation myocardial infarction through myocardial enhanced mri.

investigators will enroll 160 patients with stemi who were admitted to the chinese pla general hospital between march 2022 and marchr 2024，the investigators randomly assign eligible patients in a 1:1 ratio to either cardiomyopeptidin intervention group or control group befor primary pci. the cardiomyopeptidin intervention group patients received intravenous infusion 3 mg/(kg·d) of cardiomyopeptidin during the pci until 3 days after operation. primary end point of the study was the area of infarct size measured by cardiac magnetic resonance (cmr). and secondary endpoints include slow flow/no-reflow incidence, corrected timi frame count (ctfc), st-segment fall rate of ecg, cardiac enzymes and troponin, area of myocardial edema, microvascular obstruction, left ventricular ejection fraction, and composite cardiovascular events during the study period: all-cause death, cardiovascular death, unplanned hospitalization for heart failure, and revascularization. all adverse clinical events as well as study end points were monitored and adjudicated by the independent event committee.

Eligibility criteria:
inclusion criteria: * stemi patients: typical chest pain lasting 30 min within the previous 12 h, a clear st-segment elevation of n0.1 mv in ≥2 contiguous electrocardiographic leads, and elevated blood levels of troponin t * patients were scheduled to undergo diagnostic cardiac angiography or percutaneous coronary interventions exclusion criteria: * had once treated by ivabradine * history of myocardial infarction * mechanical complications * unable to perform myocardial mri * liver and kidney failure * malignant tumor * unconscious * patients with other significant abnormal signs, laboratory tests and clinical disease are unsuitable for participation in the study accessed by clinicians.
efficacy of platelet-rich plasma in improving postoperative scarring after cesarean delivery

Conditions: Cesarean Section Wound; Platelet-rich Plasma (PRP); Regenerative Medicine

Summary: cesarean section often leads to postoperative scarring, which can impact both physical and psychological well-being. platelet-rich plasma (prp), rich in growth factors, is used in regenerative medicine to promote healing and reduce inflammation.

background: cesarean section often leads to postoperative scarring, which can impact both physical and psychological well-being. platelet-rich plasma (prp), rich in growth factors, is used in regenerative medicine to promote healing and reduce inflammation. objective: to evaluate the efficacy of intraoperative prp in accelerating scar healing after cesarean section, using: six visual scar assessment scales (manchester, posas, vancouver, vas, nrs, reeda) hematological parameters (hemoglobin, hematocrit, leukocytes, platelets) methods: design: prospective clinical study, 100 patients undergoing cesarean section with intraoperative prp. intervention: 10 ml prp administered intraoperatively (5 ml before hysterography, 5 ml subcutaneously before skin closure). assessments: scar evaluation at day 7 and day 40 post-op using six scar scales; hematological parameters measured at both time points. statistics: wilcoxon paired samples test and pearson correlation.

Eligibility criteria:
inclusion criteria: * female patients, 18 to 45 years old. scheduled for elective or emergency cesarean section at the participating center. * singleton pregnancy (one fetus). ability to provide written informed consent. agreement to comply with the study protocol and follow-up visits at day 7 and day 40 postpartum. exclusion criteria: * known coagulation disorders (e.g., thrombocytopenia, hemophilia). platelet count below 150,000/μl at the time of enrollment. use of anticoagulant or antiplatelet therapy within 7 days before surgery. active infection at the surgical site. history of autoimmune diseases affecting wound healing (e.g., lupus, scleroderma). * known keloid formation tendency (optional: include if you want to exclude high-risk scarring profiles). * multiple pregnancies (twins, triplets, etc.). patients participating in another interventional clinical trial could interfere with outcomes. * inability to follow up for the postoperative evaluations at 7 and 40 days. refusal to consent or withdrawal of consent at any point

Keywords: cesarean section wound platelet- rich plasma regenerative medicine wound healing
evaluation of glycemic control using adjunctive continuous glucose monitoring with the dexcom g4 system

Conditions: Diabetes Mellitus

Summary: this is a prospective, non-randomized, observational study conducted in the united states.up to sixty (60) subjects will be enrolled. the purpose of the study is to evaluate long-term utility and usability of dexcom g4 continuous glucose monitoring (cgm) system. subjects will be followed monthly over a period of one year.


Eligibility criteria:
inclusion criteria: * require intensive insulin therapy, defined as use of continuous subcutaneous insulin infusion (csii) i.e. insulin pumps or multiple daily injections (mdi. * willing to refrain from use of any acetaminophen - containing (act) medication during the study, up to 24-hours before the initial sensor insertion. exclusion criteria: * have extensive skin changes/ diseases that preclude wearing the device. * dialysis.

Keywords: diabetes mellitus
a study of tarceva (erlotinib) in patients with locally advanced or metastatic non-small cell lung cancer following 4 cycles of platinum-based chemotherapy without disease progression

Conditions: Non-Small Cell Lung Cancer

Summary: this open-label, single-arm study will evaluate the safety and efficacy of tarceva (erlotinib) in patients with locally advanced or metastatic non-small cell lung cancer who have completed 4 cycles of standard platinum-based chemotherapy without progression. patients will receive tarceva at a dose of 150 mg orally daily until disease progression or unacceptable toxicity occurs.


Eligibility criteria:
inclusion criteria: * adult patients ≥ 18 years of age. * histologically documented non-small cell lung cancer (nsclc). * locally advanced or recurrent (stage iiib) or metastatic (stage iv) disease. * completion of 4 cycles of an acceptable, standard, platinum-based chemotherapy doublet without progression. * eastern cooperative oncology group (ecog) performance status 0-1. * patients of reproductive potential must agree to use effective contraception. exclusion criteria: * prior exposure to agents directed at the human epidermal growth factor receptor (her) axis (eg, gefitinib, cetuximab, trastuzumab). * prior treatment with any monoclonal antibody therapy. * any other malignancies within the previous 5 years, except for adequately treated carcinoma in situ of the cervix or squamous cell skin cancer. * clinically significant cardiovascular, hepatic, renal, or metabolic disease or active infection * pre-existing interstitial lung disease. * human immunodeficiency virus (hiv), hepatitis b virus (hbv), or hepatitis c virus (hcv) infection. * pregnant or lactating women.
haemodynamic monitoring in head and neck cancer patients

Conditions: Postoperative Complications

Summary: in order to estimate the effect of fluid management in regard to postoperative complications this observatory study will document every kind of fluid intervention peri- and intraoperatively.

the extend of mass transfusions is known to correlate with postoperative complications. however, also crystalloid and colloidal infusions are under suspicion to cause postoperative complications. this study will capture any kind of fluid intervention perioperatively as well as intraoperatively. intraoperative fluid management will be documented and matched with the operation steps respectively. the extend of fluid therapy will be correlated with general postoperative complications and especially with the survival of microvascular transplants. for this purpose, there will be four questionaires. after informed consent, the first questionaire will cover the patient's history, risk factors and previous operations. the second questionaire will cover intraoperative fluid management, documented with the actual operation step. furthermore, it will also intraoperative complications, cardiovascular-active medication. for closer monitoring, data from picco will also be included. the third questionaire will be complete in the icu covering similar content as the second questionaire. the last questionaire will cover the patient's progress on the general ward. fluid management and tube feeding, as well as general postoperative complication and flap specific complications will be noted. this study aims for 50-80 patients.

Eligibility criteria:
inclusion criteria: * 18 years old or older * admitted for head and neck surgery with microvascular transplantation due to head and neck tumors exclusion criteria: * pregnancy * underage * missing informed consent * revisions and relapse operations * non tumor-associated operations * surgery without microvascular transplants
oxygen saturation in the leg musculature affected by peripheral arterial disease during exercise on an arm ergometer

Conditions: Peripheral Arterial Disease

Summary: studies with arm ergometer (ae) training have shown benefits in the functional capacity of patients with peripheral arterial disease (pad) bypassing the main barrier to exercise in these patients, pain during walking exercise. the only study that proposed to investigate the mechanism involved in this adaptation observed that chronically training with eb promoted improvement in the oxygen saturation (sto₂) of the leg muscles during walking. however, how arm exercise could improve leg muscle sto₂ remains unknown. the goal of this study is to analyze what happens during ae on the tissue oxygen saturation (sto₂) of the leg affected by pad.


Eligibility criteria:
inclusion criteria: 1. aged ≥ 50 years; 2. with pad confirmed by clinical diagnosis and ankle-brachial index (abi) \< 0.90 in one or both limbs; 3. experiencing symptoms of intermittent claudication (ic) during walking; 4. with a body mass index (bmi) not exceeding 30 kg/m²; 5. with medical clearance to participate in the project; 6. presenting calf skinfold thickness less than 20 mm due to interference of adiposity with the light penetration of the nirs probe and finger oxygen saturation \> 95% to ensure that impaired pulmonary gas exchange does not affect the calf oxygen saturation measurements.

Keywords: exercise oxygen saturation intermittent claudication
preoxygenation with high flow nasal cannula prolongs normoxia time during induction of anaesthesia of bariatric patients and is superior to conventional preoxygenation with face mask.

Conditions: Compare Preoxygenation Methods in Bariatric Patients

Summary: to compare preoxygenation for induction of general anaesthesia with high flow nasal cannula vs preoxygenation with face mask in patients undergoing bariatric surgery. the hypothesis is that preoxygenation with high flow nasal cannula prolongs normoxia time during induction of anaeshesia and is superior to conventional preoxygenation with face mask. primary endpoint will be the time during which spo2 \> 92 %. secondary endpoint will be paco2.


Eligibility criteria:
inclusion criteria: * age over 18 * elective bariatric surgery * written consent exclusion criteria: * preexisting lung diseases, congenital heart diseases * known difficult airway * spo2 \< 92% under ambient air conditions * known diaphragmal hernia * clinically relevant reflux
medical nutrition therapy plus transgestational metformin for preventing gestational diabetes in high risk mexican women

Conditions: Pregestational Obesity (BMI > 27kg/m2); History of Polycystic Ovary Syndrome

Summary: gestational diabetes mellitus is one of the most frequent complications of pregnancy, that affect between 1 to 14% of population around the world. there is a few studies to prevent gestational diabetes mellitus in high risk women as mexican population. metformin has been used during pregnancy in women with gestational diabetes and women with polycystic ovary syndrome, with acceptable security for mother and fetus. metformin decrease the insulin resistance and weight gain, we believe that metformin may be decrease the risk of gestational diabetes mellitus in high risk women.


Eligibility criteria:
inclusion criteria: * mexican women with pregnancy \< 16 weeks of gestation, normal oral glucose tolerance 75g-2h test and 3 or more criteria: 1. body mass index \> 27 kg/m2 2. maternal age \>25 3. history of infertility with polycystic ovary syndrome 4. history of macrosomic newborn (weight \>4000g) 5. history of diabetes mellitus in first or second degree. 6. history of gestational diabetes in previous pregnancy exclusion criteria: * any form of pregestational diabetes * fasting glucose \> 126 mg/dl at first prenatal visit. * seric creatinine \> 1.5 mg/dl * hyperthyroidism * heart disease * hepatic disease * renal diseases * epilepsy * lupus * chronic hypertension.

Keywords: obesity, polycystic ovary syndrome, gestational diabetes
effect of milk oligosaccharides and bifidobacteria on the intestinal microflora of children with autism

Conditions: Autism

Summary: the purpose of this study is to determine the tolerability of dietary supplements and if these supplements can promote a healthy bacterial environment in the intestines of children with autism spectrum disorders and gastrointestinal complaints.

this study investigates the feasibility, tolerability, and effects of a dietary supplement on the intestinal flora of children with autism spectrum disorders. this study is divided into two parts, each five weeks long, with a two week break in between. during one part of the study, a prebiotic (milk oligosaccharides from bovine colostrum) will be given. during the other part of the study, the synbiotic composed of the prebiotic and probiotic (bifidobacterium infantis) will be given. stool will be analyzed at the end of each study arm to determine content of bifidobacteria. on may 8, 2018, we updated the study start and completion dates to the actual (instead of anticipated) dates. on may 30-31, 2019, we updated the study results section.

Eligibility criteria:
inclusion criteria: * autism * diarrhea and/or constipation exclusion criteria: * milk protein or other documented food allergy * lactose intolerance * compromised immunity * gi conditions (inflammatory bowel disease, celiac disease, short gut, etc.) * systemic steroid, antifungal, or antibiotic use within a month of starting the study * failure to thrive * medically prescribed diets or supplements (including probiotic use within the past month). * vegetarian or dairy restricted diet * other medical conditions (seizures, genetic disorders, liver/pancreatic disease, cystic fibrosis, etc.) * medications that interfere or alter intestinal motility or microbiota composition. * full scale intelligence quotient (iq) \<40

Keywords: probiotic prebiotic autism oligosaccharides bifidobacterium infantis
efficacy of 0.05 % cyclosporine ophthalmic emulsion compare with tear in meibomian gland dysfunction

Conditions: Meibomian Gland Dysfunction

Summary: to evaluate the efficacy of 0.05% cyclosporine ophthalmic emulsion (restasis® , allergan) versus an artificial tears alone in patients with meibomian gland dysfunction that have abnormal tear quality and quantity by subjective symptoms and signs including tear breakup time

meibomian gland dysfunction patients will divide into 2 groups. one group will have 0.05% cyclosporine opthalmic emulsion and the other will have non-preservative artificial tear twice daily, compare the result in 3 months.

Eligibility criteria:
inclusion criteria: * males or females, of legal age of consent * patient has a diagnosis of meibomian gland dysfunction with at least 1 symptom as the following; ocular burning, ocular discomfort, and grittiness * had a slit-lamp diagnosis of meibomian gland dysfunction based on the presence of one of the following * meibomian gland inflammation by lid margin or tarsal erythema, bulbar conjunctiva hyperemia, telangiectasia or thickening irregularity of the eyelid margins * meibomian gland orifice inclusion (plugging) or abnormal of secretion * non-invasive tear break up time (ntbut) with tear scope plus(keeler, windsor, uk) ≤ 8 seconds * ability to follow study instruction and likely to complete all required visits exclusion criteria: * age \< 18 years old * patients with severe ocular disease from steven johnson syndrome burn, limbal deficiency * patients used cyclosporine within past 1 year * patients used oral cyclosporine or anticholinergic drug within past 2 months * patients with hiv or autoimmune disease * patients with active ocular infections and patients with a history of herpes keratitis * patients with known or suspected hypersensitivity to any of the ingredients in the formula (cyclosporine, glycerin, castor oil, polysorbate 80, carbomer 1342) * female patients are pregnant or nursing * patients who wear contact lenses

Keywords: cyclosporine unstable tear film meibomian gland meibomian gland dysfunction
structured education for rehabilitation in intermittent claudication

Conditions: Peripheral Arterial Disease

Summary: a primary therapeutic goal for patients with intermittent claudication (ic) is to regain lost physical function through exercise rehabilitation. supervised exercise programmes can markedly improve walking capacity, but these are resource intensive, national health service provision is limited, and patients cite accessing services as a barrier to participation. increasing walking activity via a structured education programme might be a pragmatic solution for improving walking capacity, health and wellbeing in patients with ic; however, further research is needed to substantiate this. hence, the aim of this project is to develop a pragmatic education programme to increase walking in these patients and to collect data on its feasibility to inform the development of a definitive trial investigating clinical and cost effectiveness. focus groups will be conducted to inform the development of the education programme. programme components will be theoretically-underpinned and evidence-based. the development of the programme will be an iterative process involving pilot work, feedback, evaluation, and revision. the programme will then be assessed in a randomised controlled pilot study with 6-week follow-up (n=30). we will assess the feasibility of the intervention and obtain preliminary data of its impact on important outcomes (daily steps/physical activity, walking capacity, quality of life, illness perceptions).


Eligibility criteria:
inclusion criteria: * men and women aged \>18 years with intermittent claudication due to peripheral arterial disease * stable disease for \>3 months * able to provide consent * able to read and speak english to a level allowing satisfactory completion of written questionnaires and to participate in the education intervention exclusion criteria: * previous endovascular/surgical interventions * scheduled endovascular/surgical intervention * critical limb ischaemia * those whose function is uniquely impaired, e.g. wheelchair-bound patients and patients with lower-extremity amputation(s) * presence of contraindications to exercise or co-morbidities that limit exercise performance to a greater extent than the intermittent claudication (e.g. severe arthritis) * major surgery, myocardial infarction or stroke/transient ischemic attack in the previous 6 months * patients who already perform greater than 30 min of structured exercise three times weekly (self-reported)

Keywords: intermittent claudication behavior therapy walking exercise patient education randomized controlled trial